This comparison summarizes differences useful for designing and documenting studies. It does not constitute clinical guidance or a recommendation for human use.
| Feature | Semaglutide | Retatrutide |
|---|---|---|
| Main target | GLP-1 receptor | GLP-1, GIP and glucagon |
| Type | Incretin analog | Experimental triagonist |
| Focus | GLP-1 signaling | Multi-receptor interaction |
| Evidence maturity | Broad | In development |
How to interpret the evidence
Always compare species or cell line, sample size, analytical method, material purity and primary endpoints. Preclinical results should not be automatically extrapolated to humans.